Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) just unveiled an update.
Sihuan Pharmaceutical Holdings Group has announced that its subsidiary, Meiyan Space, received approval from the National Medical Products Administration of China for its new skin booster product, Dongyan. This product, which combines hyaluronic acid sodium with L-carnosine and other components, is designed to improve skin dryness and dullness. The approval is a significant milestone for Meiyan Space, enhancing its strategic product matrix and strengthening its position in the medical aesthetics industry. The global skin booster market is projected to grow significantly, with the Chinese market expected to expand rapidly, driven by increasing consumer demand for skin health management. Meiyan Space plans to continue its investment in R&D and market penetration to provide advanced and personalized medical aesthetic services.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group is a company incorporated in Bermuda, focusing on the medical aesthetics industry through its subsidiary, Meiyan Space. Meiyan Space is a comprehensive medical aesthetic platform that develops, registers, produces, and sells a wide range of aesthetic products, including fillers, contouring, and skin management solutions. The company aims to lead the medical aesthetics market in China by leveraging pharmaceutical rigor and innovation.
Average Trading Volume: 89,245,817
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.72B
Learn more about 0460 stock on TipRanks’ Stock Analysis page.